CTCs
The firm believes its Orion system's combination of multiplexing, data quality, and throughput will help it carve out a space in an increasingly crowded market.
The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.
Plus Therapeutics, Biocept Ink Lab Services Agreement for ReSPECT-LM Trial
Biocept will test patients with its CNSide cerebrospinal fluid cell capture assay to evaluate responses to Plus' radiotherapy drug candidate.
BioMark Diagnostics, Icahn Mount Sinai to Develop Multiomic Lung Cancer Tests
The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics.
Genetron Highlights New Minimal Residual Disease Data, Sets Plans for Solid Tumor Testing in China
Premium
The company shared new liver cancer data in a recent journal letter, demonstrating high performance for its tumor-informed approach.